On Nov. 30, the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.